Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Gerald S. Falchook, MD, MS
Director, Drug Development
Dr. Falchook completed his oncology training at MD Anderson Cancer Center, where he also served as a faculty member for six years, developing investigator-initiated clinical trials, as well as collaborating with pharma/biotech industry partners to bring promising new drugs to cancer patients.
Dr. Falchook has been the principal investigator or co-investigator of more than 160 clinical studies, including the first-in-human studies and regimens that have received FDA approval. His research has been published extensively, with more than 90 publications in peer-reviewed journals, as well as more than 150 abstracts at national and international conferences.